IN-VIVO MEASUREMENT OF THE POTENTIAL DOUBLING TIME BY FLOW-CYTOMETRIC IN OROPHARYNGEAL CANCER TREATED BY CONVENTIONAL RADIOTHERAPY

被引:50
作者
BOURHIS, J
WILSON, G
WIBAULT, P
BOSQ, J
CHAVAUDRA, N
JANOT, F
LUBOINSKI, B
ESCHWEGE, F
MALAISE, EP
机构
[1] INST GUSTAVE ROUSSY,INSERM 247,F-94800 VILLEJUIF,FRANCE
[2] MT VERNON HOSP,GRAY CAMPAIGN,NORTHWOOD HA6 2RN,MIDDX,ENGLAND
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 1993年 / 26卷 / 05期
关键词
POTENTIAL DOUBLING TIME; OROPHARYNX; CONVENTIONAL RADIOTHERAPY; LABELING INDEX;
D O I
10.1016/0360-3016(93)90494-G
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Experimental and clinical studies suggest that the Pre-treatment potential doubling time could be predictive of tumor control in patients treated by conventional radiotherapy and could help to identify the rapidly growing tumors for which accelerated radiotherapy is required. Methods and Materials: To test this hypothesis, we studied prospectively 48 patients with a squamous cell carcinoma of the oropharynx and treated by conventional radiotherapy (70 Gy/7 weeks). The duration of S phase, the labeling index and the potential doubling time were obtained by flowcytometry measurements of a tumor biopsy obtained after injection of 200 mg bromodeoxyuridine to the patient. Results: Three parameters were significantly associated with an increased risk of relapse namely the tumors size (T4; p < 0.01), the nodal status (greater-than-or-equal-to N2; p < 0.05) and the site of the primary within the oropharynx (p = 0.08). The S phase, labeling index, DNA index and potential doubling time were not significantly associated with an increased risk of relapse. However when considering only the T2 subgroup of patients, high labeling indexes and short potential doubling time were associated with an increased risk of relapse: the mean pre-treatment potential doubling time of the tumors which relapsed was 3.21 versus 5.5 days when there was no evidence of local relapse (p < 0.05). The mean labeling index for the group of tumors associated with a tumor recurrence was 11.7% compared to 7.3% when there was no evidence of relapse (p = 0.02). Conclusion: Factors other than proliferation play a role in determining the outcome of oropharyngeal cancers treated by conventional radiotherapy. However there was a significant correlation between short potential doubling time, high labeling index and tumor recurrence in the T2 subgroup of patients. The finding of significance for potential doubling time and labeling index in the T2 subset of tumors may be a reflexion of the more homogeneneous nature of these tumors with regard to prognostic variables.
引用
收藏
页码:793 / 799
页数:7
相关论文
共 31 条
  • [1] SPLIT-COURSE VERSUS CONTINUOUS-COURSE IRRADIATION IN THE POSTOPERATIVE SETTING FOR SQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK
    AMDUR, RJ
    PARSONS, JT
    MENDENHALL, WM
    MILLION, RR
    CASSISI, NJ
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1989, 17 (02): : 279 - 285
  • [2] THE EFFECT OF TREATMENT TIME AND TREATMENT INTERRUPTION ON TUMOR-CONTROL FOLLOWING RADICAL RADIOTHERAPY OF LARYNGEAL-CANCER
    BARTON, MB
    KEANE, TJ
    GADALLA, T
    MAKI, E
    [J]. RADIOTHERAPY AND ONCOLOGY, 1992, 23 (03) : 137 - 143
  • [3] THE PREDICTIVE VALUE OF CELL KINETIC MEASUREMENTS IN A EUROPEAN TRIAL OF ACCELERATED FRACTIONATION IN ADVANCED HEAD AND NECK TUMORS - AN INTERIM-REPORT
    BEGG, AC
    HOFLAND, I
    MOONEN, L
    BARTELINK, H
    SCHRAUB, S
    BONTEMPS, P
    LEFUR, R
    VANDENBOGAERT, W
    CASPERS, R
    VANGLABBEKE, M
    HORIOT, JC
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1990, 19 (06): : 1449 - 1453
  • [4] HUMAN-TUMOR CELL-KINETICS USING A MONOCLONAL-ANTIBODY AGAINST IODODEOXYURIDINE - INTRATUMOR SAMPLING VARIATIONS
    BEGG, AC
    MOONEN, L
    HOFLAND, I
    DESSING, M
    BARTELINK, H
    [J]. RADIOTHERAPY AND ONCOLOGY, 1988, 11 (04) : 337 - 347
  • [5] A METHOD TO MEASURE THE DURATION OF DNA-SYNTHESIS AND THE POTENTIAL DOUBLING TIME FROM A SINGLE SAMPLE
    BEGG, AC
    MCNALLY, NJ
    SHRIEVE, DC
    KARCHER, H
    [J]. CYTOMETRY, 1985, 6 (06): : 620 - 626
  • [6] BENNET M, IN PRESS BR J CANCER
  • [7] BOURHIS J, 1991, B CANCER, V78, P1045
  • [8] CONTINUOUS, HYPERFRACTIONATED, ACCELERATED RADIOTHERAPY (CHART) - AN INTERIM-REPORT UPON LATE MORBIDITY
    DISCHE, S
    SAUNDERS, MI
    [J]. RADIOTHERAPY AND ONCOLOGY, 1989, 16 (01) : 67 - 74
  • [9] THE RATIONALE FOR CONTINUOUS, HYPERFRACTIONATED, ACCELERATED RADIOTHERAPY (CHART)
    DISCHE, S
    SAUNDERS, MI
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1990, 19 (05): : 1317 - 1320
  • [10] THE PHANTOM OF TUMOR TREATMENT - CONTINUALLY RAPID PROLIFERATION UNMASKED
    FOWLER, JF
    [J]. RADIOTHERAPY AND ONCOLOGY, 1991, 22 (03) : 156 - 158